12:00 AM
Nov 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III AURA trial in 1,523 patients showed that that once-daily 500 ug oral Daxas for 52 weeks significantly improved mean pre-bronchodilator FEV1 by 39 mL vs. placebo (46 vs. 8 mL, p<0.001). The mean rate of moderate and/or severe exacerbations/patient/year was 1.1 for Daxas vs. 1.3 for placebo (p=0.028). Data were presented at the American College of Chest Physicians meeting in San Diego. Nycomed...

Read the full 332 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >